title: Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
abstract: BACKGROUND
  There are no published MRI studies comparing interferon beta 1b (IFNbeta-1b) and glatiramer acetate (GA) for treatment of relapsing multiple sclerosis (MS).
  
  
  OBJECTIVE
  To compare the efficacy of IFNbeta-1b and GA for suppression of MS disease activity as evidenced on frequent brain MRI.
  
  
  METHODS
  A total of 75 patients with relapsing-remitting MS or clinically isolated syndromes were randomized to standard doses of IFNbeta-1b or GA and followed by monthly brain MRI for up to 2 years with a protocol optimized to detect enhancement. The primary outcome was the number of combined active lesions (CAL) per patient per scan during the first year, which included all enhancing lesions and nonenhancing new T2/fluid-attenuated inversion recovery (FLAIR) lesions. Secondary outcomes were the number of new lesions and clinical exacerbations over 2 years.
  
  
  RESULTS
  Baseline characteristics were similar between the groups. The primary outcome showed similar median (75th percentile) CAL per patient per scan for months 1-12, 0.63 (2.76) for IFNbeta-1b, and 0.58 (2.45) for GA (p = 0.58). There were no differences in new lesion or clinical relapses for 2 years. Only 4.4% of CAL on monthly MRI scans were nonenhancing new T2/FLAIR lesions.
  
  
  CONCLUSIONS
  Patients with relapsing multiple sclerosis randomized to interferon beta 1b or glatiramer acetate showed similar MRI and clinical activity.
authors.affiliation: Department of Neurology and Neuroscience, UMDNJ-New Jersey Medical School, Newark, USA. cadavidi@umdnj.edu
authors.forename: D
authors.initials: D
authors.lastname: Cadavid
authors.forename: L J
authors.initials: LJ
authors.lastname: Wolansky
authors.forename: J
authors.initials: J
authors.lastname: Skurnick
authors.forename: J
authors.initials: J
authors.lastname: Lincoln
authors.forename: J
authors.initials: J
authors.lastname: Cheriyan
authors.forename: K
authors.initials: K
authors.lastname: Szczepanowski
authors.forename: S S
authors.initials: SS
authors.lastname: Kamin
authors.forename: A R
authors.initials: AR
authors.lastname: Pachner
authors.forename: J
authors.initials: J
authors.lastname: Halper
authors.forename: S D
authors.initials: SD
authors.lastname: Cook
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D002490:Central Nervous System / Q000187:drug effects* / Q000276:immunology / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D017063:Outcome Assessment, Health Care / Q000379:methods; D010455:Peptides / Q000008:administration & dosage*; D011237:Predictive Value of Tests; D055502:Secondary Prevention; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta